Mr. Hendrick has been with Cetya for 9 years, serving as an advisor to Cetya for one year prior to becoming its CEO and Board member in July 2014.  Prior to Cetya, Mr. Hendrick spent over 20 years working for Genzyme Corporation, most recently as the Vice President and General Manager of Early Development for the Oncology business. During his time at Genzyme, Mr. Hendrick served in a wide variety of roles, managing a small tissue culture production facility, starting a phospholipid supply business, in-licensing gene therapy assets and Mr. Hendrick was a principal in the creation of Genzyme Molecular Oncology, a tracking stock within Genzyme. Mr. Hendrick worked for Integrated Genetics for six years prior to its merger with Genzyme in 1989 and in research for the Life Sciences division of Millipore Corporation for 11 years before joining Integrated Genetics and the biotechnology industry in 1983. Mr. Hendrick holds a B.S. in Life Sciences from the Massachusetts Institute of Technology and a M.B.A. from Northeastern University.